Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1816-1823

  Garcia Parra, Rita ^a,c   Wood, David ^b   Shah, Rajal B ^b   Siddiqui, Javed ^b   Hussain, Hero ^a   Park, Hyunjin ^a,d   Desmond, Timothy ^a   Meyer, Charles ^a   Piert, Morand ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Gachon University College of Medicine   (South Korea)

Author keywords

18F FAZA; CAIX; Fluoroazomycin arabinoside; HIF 1 ; Hypoxia; Immunohistochemistry; MIB 1 Ki 67; PET CT; PET MRI fusion; Prostate cancer

Indexed keywords

ARABINOSIDE; CARBONATE DEHYDRATASE IX; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DIURESIS; EX VIVO STUDY; GLEASON SCORE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSTATE CANCER; PROSTATECTOMY; RADIOACTIVITY; STAINING; TISSUE MICROARRAY;

AGED; CELL HYPOXIA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 80455174743     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1876-z     Document Type: Article

References (47)

1. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9. (Pubitemid 35246449)
2. Lekas A, Lazaris AC, Deliveliotis C, Chrisofos M, Zoubouli C, Lapas D, et al. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 2006;26:2989-93. (Pubitemid 44161791)
3. Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO (2) study. Cancer 2000;89:2018-24.
4. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2009;105:8-13.
5. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 2006;65:91-9.
6. Arabi M, Piert M. Hypoxia PET/CT imaging: implications for radiation oncology. Q J Nucl Med Mol Imaging 2010;54:500-9.
7. Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PETin head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007;34:1566-75. (Pubitemid 47476913)
8. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaging using 1-alpha-D: - (5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009;36:1565-73.
9. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51. (Pubitemid 47380112)
10. Piert M. Hypoxia imaging. In: Wahl RL, editor. Principles and practices of PET and PET/CT. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
11. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006;50:28-43.
12. Beck R, Röper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48:973-80. (Pubitemid 46909926)
13. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60. (Pubitemid 43073432)
14. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610-6. (Pubitemid 350206795)
15. Li Y, Wang H, Oosterwijk E, Selman Y, Mira JC, Medrano T, et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 2009;386:488-92.
16. Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, et al. Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 2010;75:786-92.
17. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxiainducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005;11:7658-63. (Pubitemid 41611607)
18. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
19. Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007;178:677-82. (Pubitemid 47030492)
20. *) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol 2009;85:805-13.
21. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004;3:164-7. (Pubitemid 40268690)
22. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342-51.
23. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009;50:1585-93.
24. Park H, Piert MR, Khan A, Shah R, Hussain H, Siddiqui J, et al. Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol 2008;15:1027-39. (Pubitemid 351953912)
25. Chenevert TL, Welsh RC. Diffusion tensor MR imaging. In: Haacke EM, editor. Current protocols in magnetic resonance imaging. Wiley Online Library; 2004.
26. Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1997;1:195-206.
27. Park H, Meyer CR, Wood D, Khan A, Shah R, Hussain H, et al. Validation of automatic target volume definition as demonstrated for (11) C-choline PET/CT of human prostate cancer using multi-modality fusion techniques. Acad Radiol 2010;17:614-23.
28. Shah R, Bassily N, Wei J, Mucci NR, Montie JE, Sanda MG, et al. Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology 2000;56:721-5.
29. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-5. (Pubitemid 47395131)
30. Fleming ID, Cooper JS, Henson DE. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott, Raven;1998.
31. May M, Siegsmund M, Hammermann F, Loy V, Gunia S. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007;41:375-81. (Pubitemid 350034696)
32. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-73. (Pubitemid 32422941)
33. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7. (Pubitemid 38221131)
34. Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxiainducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003;116:1936-9. (Pubitemid 38159901)
35. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 2006;66:11263-70. (Pubitemid 46009955)
36. Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, et al. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate 2007;67:1091-8. (Pubitemid 46983338)
37. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007;22:559-72. (Pubitemid 46647268)
38. Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 2009;15:6128-36.
39. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9. (Pubitemid 32783244)
40. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334-40. (Pubitemid 43327764)
41. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120:1451-8. (Pubitemid 46355379)
42. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358-68.
43. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010;29:6509-21.
44. Delacruz J, Mikulski R, Tu C, Li Y, Wang H, Shiverick KT, et al. Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry. Anal Biochem 2010;403:74-8.
45. Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD, et al. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology 2007;70:832-7. (Pubitemid 350030244)
46. Smyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis 2010;13:178-81.
47. John SS, Zietman AL, Shipley WU, Harisinghani MG. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys 2008;71:S43-7. (Pubitemid 351491428)